Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient‐reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open‐label trial
Article in JEADV Clinical Practice (February 2024)
The most recent citing publications are shown below. View all 50 publications that cite this research output on Dimensions.
Article in JEADV Clinical Practice (February 2024)
Article in Contact Dermatitis (January 2024)
Article in Journal of the European Academy of Dermatology and Venereology (December 2023)